Blockade by NIP-142, an Antiarrhythmic Agent, of Carbachol-Induced Atrial Action Potential Shortening and GIRK1/4 Channel-Reference-Cited by-同舟云学术

Blockade by NIP-142, an Antiarrhythmic Agent, of Carbachol-Induced Atrial Action Potential Shortening and GIRK1/4 Channel

Published:2006 Issue:4 Volume:101 Page:303-310
ISSN:1347-8613
Container-title:Journal of Pharmacological Sciences
language:en
Short-container-title:J Pharmacol Sci

Author:

Matsuda Tomoyuki,Ito Mie,Ishimaru Sayoko,Tsuruoka Noriko,Saito Tomoaki,Iida-Tanaka Naoko,Hashimoto Norio,Yamashita Toru,Tsuruzoe Nobutomo,Tanaka Hikaru,Shigenobu Koki

Publisher

Japanese Pharmacological Society

Subject

Pharmacology,Molecular Medicine

Reference29 articles.

1. 1 Sugimoto T. Epidemiology of atrial fibrillation. In: Hayakawa K, Kasanuki H, editors. Atrial fibrillation, flutter, and tachycardia. Tokyo: Igaku-Shoin Ltd; 1999. p. 14–18.

2. Comparison of the safety and efficacy of flecamide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter

3. Propafenone for Conversion and Prophylaxis of Atrial Fibrillation

4. 4 Lenz T, Hilleman D. Dofetilide. A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter. Drugs Today (Barc). 2000;36:759–771.

5. 5 Brown M, Smith W, Lubbe W, Norris R. Amiodarone-induced torsades de pointes. Eur Heart J. 1986;7:234–239.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Targeting of Potassium Channels;Ion Channels as Targets in Drug Discovery;2024

2. Licorice metabolite 18β‐glycyrrhetinic acid activates G protein‐gated inwardly rectifying K⁺ channels;British Journal of Pharmacology;2023-09-29

3. Characterization of VU0468554, a New Selective Inhibitor of Cardiac G Protein–Gated Inwardly Rectifying K+ Channels;Molecular Pharmacology;2021-09-09

4. Advances in Targeting GIRK Channels in Disease;Trends in Pharmacological Sciences;2021-03

5. Kir Channel Molecular Physiology, Pharmacology, and Therapeutic Implications;Pharmacology of Potassium Channels;2021